Ovarian cancer in BRCA1 and BRCA2 gene mutation carriers: Analysis of prognostic factors and survival

Nicoletta Biglia, Paola Sgandurra, Valentina Elisabetta Bounous, Furio Maggiorotto, Eleonora Piva, Emanuele Pivetta, Riccardo Ponzone, Barbara Pasini

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Objectives: To compare clinical-pathological characteristics and outcome between sporadic ovarian cancer and ovarian cancer in patents with hereditary breast and ovarian cancer syndrome (HBOC). Methods: Twenty-four patients with ovarian cancer treated between 2000 and 2009 who tested positive for BRCA1/2 mutation (BRCA+) and a control group of 64 age-matched patients with no family history of breast/ovarian cancer (controls) were enrolled. Clinical-pathological characteristics, surgical outcome, overall (OS), and progression-free survival (PFS) were compared between the two groups. Results: The high-grade serous histotype was more represented in BRCA+ than in controls (70.8% versus 53.1%) (p > 0.05). BRCA+ cancers were more frequently diagnosed at stage II than controls (20.83% versus 4.69%) (p = 0.024). Radical primary surgery was performed in 70% of women in both groups, with no difference in debulking results. In patients undergoing surgery after neoadjuvant chemotherapy, in all BRCA+ patients, optimal cytoreduction was achieved (versus 70% of the controls). PFS was significantly longer for BRCA+ patients compared to controls (60 months versus 22 months; p = 0.039). No significant difference was observed in OS between BRCA+ patients and controls. Conclusions: At a median follow-up time of 46 months, BRCA+ patients have a better prognosis than controls in terms of PFS. Higher chemosensitivity of BRCA+ tumours was observed.

Original languageEnglish
Article number639
Journalecancermedicalscience
Volume10
DOIs
Publication statusPublished - May 3 2016

Fingerprint

BRCA2 Gene
BRCA1 Gene
Survival Analysis
Ovarian Neoplasms
Mutation
Disease-Free Survival
Hereditary Breast and Ovarian Cancer Syndrome
Patents
Neoplasms
Breast Neoplasms
Drug Therapy
Control Groups

Keywords

  • BRCA1
  • BRCA2
  • Gene mutations
  • Hereditary breast and ovarian cancer syndrome
  • Ovarian cancer
  • Prognosis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Ovarian cancer in BRCA1 and BRCA2 gene mutation carriers : Analysis of prognostic factors and survival. / Biglia, Nicoletta; Sgandurra, Paola; Bounous, Valentina Elisabetta; Maggiorotto, Furio; Piva, Eleonora; Pivetta, Emanuele; Ponzone, Riccardo; Pasini, Barbara.

In: ecancermedicalscience, Vol. 10, 639, 03.05.2016.

Research output: Contribution to journalArticle

Biglia, Nicoletta ; Sgandurra, Paola ; Bounous, Valentina Elisabetta ; Maggiorotto, Furio ; Piva, Eleonora ; Pivetta, Emanuele ; Ponzone, Riccardo ; Pasini, Barbara. / Ovarian cancer in BRCA1 and BRCA2 gene mutation carriers : Analysis of prognostic factors and survival. In: ecancermedicalscience. 2016 ; Vol. 10.
@article{78c5d14405974e13b0bda317cf35aca7,
title = "Ovarian cancer in BRCA1 and BRCA2 gene mutation carriers: Analysis of prognostic factors and survival",
abstract = "Objectives: To compare clinical-pathological characteristics and outcome between sporadic ovarian cancer and ovarian cancer in patents with hereditary breast and ovarian cancer syndrome (HBOC). Methods: Twenty-four patients with ovarian cancer treated between 2000 and 2009 who tested positive for BRCA1/2 mutation (BRCA+) and a control group of 64 age-matched patients with no family history of breast/ovarian cancer (controls) were enrolled. Clinical-pathological characteristics, surgical outcome, overall (OS), and progression-free survival (PFS) were compared between the two groups. Results: The high-grade serous histotype was more represented in BRCA+ than in controls (70.8{\%} versus 53.1{\%}) (p > 0.05). BRCA+ cancers were more frequently diagnosed at stage II than controls (20.83{\%} versus 4.69{\%}) (p = 0.024). Radical primary surgery was performed in 70{\%} of women in both groups, with no difference in debulking results. In patients undergoing surgery after neoadjuvant chemotherapy, in all BRCA+ patients, optimal cytoreduction was achieved (versus 70{\%} of the controls). PFS was significantly longer for BRCA+ patients compared to controls (60 months versus 22 months; p = 0.039). No significant difference was observed in OS between BRCA+ patients and controls. Conclusions: At a median follow-up time of 46 months, BRCA+ patients have a better prognosis than controls in terms of PFS. Higher chemosensitivity of BRCA+ tumours was observed.",
keywords = "BRCA1, BRCA2, Gene mutations, Hereditary breast and ovarian cancer syndrome, Ovarian cancer, Prognosis",
author = "Nicoletta Biglia and Paola Sgandurra and Bounous, {Valentina Elisabetta} and Furio Maggiorotto and Eleonora Piva and Emanuele Pivetta and Riccardo Ponzone and Barbara Pasini",
year = "2016",
month = "5",
day = "3",
doi = "10.3332/ecancer.2016.639",
language = "English",
volume = "10",
journal = "ecancermedicalscience",
issn = "1754-6605",
publisher = "Cancer Intellilgence",

}

TY - JOUR

T1 - Ovarian cancer in BRCA1 and BRCA2 gene mutation carriers

T2 - Analysis of prognostic factors and survival

AU - Biglia, Nicoletta

AU - Sgandurra, Paola

AU - Bounous, Valentina Elisabetta

AU - Maggiorotto, Furio

AU - Piva, Eleonora

AU - Pivetta, Emanuele

AU - Ponzone, Riccardo

AU - Pasini, Barbara

PY - 2016/5/3

Y1 - 2016/5/3

N2 - Objectives: To compare clinical-pathological characteristics and outcome between sporadic ovarian cancer and ovarian cancer in patents with hereditary breast and ovarian cancer syndrome (HBOC). Methods: Twenty-four patients with ovarian cancer treated between 2000 and 2009 who tested positive for BRCA1/2 mutation (BRCA+) and a control group of 64 age-matched patients with no family history of breast/ovarian cancer (controls) were enrolled. Clinical-pathological characteristics, surgical outcome, overall (OS), and progression-free survival (PFS) were compared between the two groups. Results: The high-grade serous histotype was more represented in BRCA+ than in controls (70.8% versus 53.1%) (p > 0.05). BRCA+ cancers were more frequently diagnosed at stage II than controls (20.83% versus 4.69%) (p = 0.024). Radical primary surgery was performed in 70% of women in both groups, with no difference in debulking results. In patients undergoing surgery after neoadjuvant chemotherapy, in all BRCA+ patients, optimal cytoreduction was achieved (versus 70% of the controls). PFS was significantly longer for BRCA+ patients compared to controls (60 months versus 22 months; p = 0.039). No significant difference was observed in OS between BRCA+ patients and controls. Conclusions: At a median follow-up time of 46 months, BRCA+ patients have a better prognosis than controls in terms of PFS. Higher chemosensitivity of BRCA+ tumours was observed.

AB - Objectives: To compare clinical-pathological characteristics and outcome between sporadic ovarian cancer and ovarian cancer in patents with hereditary breast and ovarian cancer syndrome (HBOC). Methods: Twenty-four patients with ovarian cancer treated between 2000 and 2009 who tested positive for BRCA1/2 mutation (BRCA+) and a control group of 64 age-matched patients with no family history of breast/ovarian cancer (controls) were enrolled. Clinical-pathological characteristics, surgical outcome, overall (OS), and progression-free survival (PFS) were compared between the two groups. Results: The high-grade serous histotype was more represented in BRCA+ than in controls (70.8% versus 53.1%) (p > 0.05). BRCA+ cancers were more frequently diagnosed at stage II than controls (20.83% versus 4.69%) (p = 0.024). Radical primary surgery was performed in 70% of women in both groups, with no difference in debulking results. In patients undergoing surgery after neoadjuvant chemotherapy, in all BRCA+ patients, optimal cytoreduction was achieved (versus 70% of the controls). PFS was significantly longer for BRCA+ patients compared to controls (60 months versus 22 months; p = 0.039). No significant difference was observed in OS between BRCA+ patients and controls. Conclusions: At a median follow-up time of 46 months, BRCA+ patients have a better prognosis than controls in terms of PFS. Higher chemosensitivity of BRCA+ tumours was observed.

KW - BRCA1

KW - BRCA2

KW - Gene mutations

KW - Hereditary breast and ovarian cancer syndrome

KW - Ovarian cancer

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84978937991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978937991&partnerID=8YFLogxK

U2 - 10.3332/ecancer.2016.639

DO - 10.3332/ecancer.2016.639

M3 - Article

AN - SCOPUS:84978937991

VL - 10

JO - ecancermedicalscience

JF - ecancermedicalscience

SN - 1754-6605

M1 - 639

ER -